The text discusses the emergence of the novel coronavirus SARS-CoV-2, causing COVID-19, and the global impact of the ongoing pandemic. It highlights the development and testing of various COVID-19 vaccines targeting the Spike glycoprotein of the virus, particularly the S1 subunit containing the receptor-binding domain (RBD) and the S2 subunit for membrane fusion. The identification of neutralizing antibodies and T cell responses in recovered patients emphasizes the importance of the S1 subunit as a key target for vaccine development. The text also addresses the emergence of various SARS-CoV-2 variants, including the concerning Omicron variant, leading to subsequent waves of the pandemic in several countries. It discusses the development of over 100 COVID-19 vaccines, with a focus on enhancing cellular immune responses against the virus. The study highlighted the use of an autophagy-inducing peptide called AIP-C5 to enhance T cell immune responses against the S protein of SARS-CoV-2, resulting in improved protective efficacy in animal models. The research also evaluated the protective effects of adenovirus vectors expressing the Spike protein against SARS-CoV-2 variants in mice and golden Syrian hamsters. Additionally, the text emphasizes the importance of developing next-generation COVID-19 vaccines to effectively target virus variants and control the pandemic.